Literature DB >> 27236363

Regulation of the T Cell Response by CD39.

Maisa C Takenaka1, Simon Robson2, Francisco J Quintana3.   

Abstract

The ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, or CD39) catalyzes the phosphohydrolysis of extracellular ATP (eATP) and ADP (eADP) released under conditions of inflammatory stress and cell injury. CD39 generates AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine. These ectonucleotidases have a major impact on the dynamic equilibrium of proinflammatory eATP and ADP nucleotides versus immunosuppressive adenosine nucleosides. Indeed, CD39 plays a dominant role in the purinergic regulation of inflammation and the immune response because its expression is influenced by genetic and environmental factors. We review the specific role of CD39 in the kinetic regulation of cellular immune responses in the evolution of disease. We focus on the effects of CD39 on T cells and explore potential clinical applications in autoimmunity, chronic infections, and cancer.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27236363      PMCID: PMC5215082          DOI: 10.1016/j.it.2016.04.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  115 in total

1.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

Review 2.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Authors:  Silvia Deaglio; Simon C Robson
Journal:  Adv Pharmacol       Date:  2011

3.  CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness.

Authors:  Norikatsu Mizumoto; Tadashi Kumamoto; Simon C Robson; Jean Sévigny; Hiroyuki Matsue; Keiichi Enjyoji; Akira Takashima
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

4.  Extracellular ATP in T-lymphocyte activation: possible role in effector functions.

Authors:  A Filippini; R E Taffs; M V Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

6.  Dependence of immunoglobulin class switch recombination in B cells on vesicular release of ATP and CD73 ectonucleotidase activity.

Authors:  Francesca Schena; Stefano Volpi; Caterina Elisa Faliti; Federica Penco; Spartaco Santi; Michele Proietti; Ursula Schenk; Gianluca Damonte; Annalisa Salis; Marta Bellotti; Franco Fais; Claudya Tenca; Marco Gattorno; Hermann Eibel; Marta Rizzi; Klaus Warnatz; Marco Idzko; Cemil Korcan Ayata; Mirzokhid Rakhmanov; Thierry Galli; Alberto Martini; Marco Canossa; Fabio Grassi; Elisabetta Traggiai
Journal:  Cell Rep       Date:  2013-06-13       Impact factor: 9.423

7.  The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration.

Authors:  Katrin Färber; Sören Markworth; Ulrike Pannasch; Christiane Nolte; Vincent Prinz; Golo Kronenberg; Karen Gertz; Matthias Endres; Ingo Bechmann; Keiichi Enjyoji; Simon C Robson; Helmut Kettenmann
Journal:  Glia       Date:  2008-02       Impact factor: 7.452

8.  A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses.

Authors:  Guangxun Meng; Fuping Zhang; Ivan Fuss; Atsushi Kitani; Warren Strober
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

9.  In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling.

Authors:  Henry Yim Wu; Francisco J Quintana; Andre Pires da Cunha; Benjamin T Dake; Thomas Koeglsperger; Sarah C Starossom; Howard L Weiner
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

10.  CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.

Authors:  Prakash K Gupta; Jernej Godec; David Wolski; Emily Adland; Kathleen Yates; Kristen E Pauken; Cormac Cosgrove; Carola Ledderose; Wolfgang G Junger; Simon C Robson; E John Wherry; Galit Alter; Philip J R Goulder; Paul Klenerman; Arlene H Sharpe; Georg M Lauer; W Nicholas Haining
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

View more
  69 in total

Review 1.  Control of immune-mediated pathology via the aryl hydrocarbon receptor.

Authors:  Michael A Wheeler; Veit Rothhammer; Francisco J Quintana
Journal:  J Biol Chem       Date:  2017-06-14       Impact factor: 5.157

Review 2.  Metabolites: deciphering the molecular language between DCs and their environment.

Authors:  Lucía Minarrieta; Peyman Ghorbani; Tim Sparwasser; Luciana Berod
Journal:  Semin Immunopathol       Date:  2016-12-05       Impact factor: 9.623

3.  Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.

Authors:  David M Woods; Andressa S Laino; Aidan Winters; Jason Alexandre; Daniel Freeman; Vinay Rao; Santi S Adavani; Jeffery S Weber; Pratip K Chattopadhyay
Journal:  JCI Insight       Date:  2020-06-04

Review 4.  Role of AHR and HIF-1α in Glioblastoma Metabolism.

Authors:  Galina Gabriely; Michael A Wheeler; Maisa C Takenaka; Francisco J Quintana
Journal:  Trends Endocrinol Metab       Date:  2017-03-16       Impact factor: 12.015

5.  Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Authors:  Xian-Yang Li; Achim K Moesta; Christos Xiao; Kyohei Nakamura; Mika Casey; Haiyan Zhang; Jason Madore; Ailin Lepletier; Amelia Roman Aguilera; Ashmitha Sundarrajan; Celia Jacoberger-Foissac; Clifford Wong; Tracy Dela Cruz; Megan Welch; Alana G Lerner; Bradley N Spatola; Vanessa B Soros; John Corbin; Ana C Anderson; Maike Effern; Michael Hölzel; Simon C Robson; Rebecca L Johnston; Nicola Waddell; Corey Smith; Tobias Bald; Nishamol Geetha; Courtney Beers; Michele W L Teng; Mark J Smyth
Journal:  Cancer Discov       Date:  2019-11-07       Impact factor: 39.397

6.  Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression.

Authors:  Benjamin J Schmiedel; Divya Singh; Ariel Madrigal; Alan G Valdovino-Gonzalez; Brandie M White; Jose Zapardiel-Gonzalo; Brendan Ha; Gokmen Altay; Jason A Greenbaum; Graham McVicker; Grégory Seumois; Anjana Rao; Mitchell Kronenberg; Bjoern Peters; Pandurangan Vijayanand
Journal:  Cell       Date:  2018-11-15       Impact factor: 41.582

Review 7.  Tolerogenic dendritic cells.

Authors:  Maisa C Takenaka; Francisco J Quintana
Journal:  Semin Immunopathol       Date:  2016-09-19       Impact factor: 9.623

Review 8.  Purinergic signaling during intestinal inflammation.

Authors:  Maria Serena Longhi; Alan Moss; Zhenghui Gordon Jiang; Simon C Robson
Journal:  J Mol Med (Berl)       Date:  2017-05-26       Impact factor: 4.599

9.  GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.

Authors:  Marie Jo Halaby; Kebria Hezaveh; Sara Lamorte; M Teresa Ciudad; Andreas Kloetgen; Bethany L MacLeod; Mengdi Guo; Ankur Chakravarthy; Tiago Da Silva Medina; Stefano Ugel; Aristotelis Tsirigos; Vincenzo Bronte; David H Munn; Trevor J Pugh; Daniel D De Carvalho; Marcus O Butler; Pamela S Ohashi; David G Brooks; Tracy L McGaha
Journal:  Sci Immunol       Date:  2019-12-13

10.  Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease.

Authors:  Mette D Hazenberg; Nienke J E Haverkate; Yannouck F van Lier; Hergen Spits; Lisette Krabbendam; Willem A Bemelman; Christianne J Buskens; Bianca Blom; Medya M Shikhagaie
Journal:  Blood Adv       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.